Development of extended release matrices of rifampicin using hot melt extrusion technique.

Simple item page
dc.contributor.authorSharma, Vanita J
dc.contributor.authorAmin, Purnima D
dc.date.accessioned2014-06-11T04:53:05Z
dc.date.available2014-06-11T04:53:05Z
dc.date.issued2013-10
dc.description.abstractTuberculosis has metamorphosized over the decades from drug resistant to multidrug resistant to the lethal extensively drug resistant forms lately. With scarce newer anti-TB drugs emerging, there is a pressing need to ameliorate the current treatment therapy by modulating the formulation approaches towards the first line treatment drugs. In the present study an attempt has been made to formulate Rifampicin (RIF), the first line treatment drug for TB as an extended release oral formulation using melt extrusion technique. The total dose of RIF was divided into two components- Immediate release (IR) pellets of RIF as the loading dose (300mg) and extended release tablet as the maintenance dose (150mg). Extrusion trials were conducted using various class of extrudable polymers (cellulose, polyvinyl acetate, polyethylene oxide, poly(meth)acrylates). Based on the preliminary findings, IR pellets were formulated using Eudragit EPO whereas hydroxylpropyl cellulose (HPC) was further explored as the matrix former. The release rate was modified using addition of hydrophilic pH independent release modifier. The formulation was characterized with respect to in vitro dissolution behavior, thermal and chemical stability, miscibility, drug-polymer interactions and surface morphology followed by stability studies. The loading dose could adequately release RIF initially whereas a combination of hydrophilic pH independent polymer of varying viscosity could successfully control RIF release over 24 hours following zero order release mechanism. The developed formulation exhibited content uniformity, physical and chemical stability over a period of six months. The application of melt extrusion for developing extended release matrices for anti-TB drugs like RIF was sought. Melt extrusion being a continuous manufacturing process could be scaled up commercially thus enhancing the feasibility of the designed formulation.en_US
dc.identifier.citationSharma Vanita J, Amin Purnima D. Development of extended release matrices of rifampicin using hot melt extrusion technique. Journal of Applied Pharmaceutical Science. 2013 Oct; 3(10): 30-38.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/151898
dc.language.isoenen_US
dc.source.urihttps://www.japsonline.com/counter.php?aid=1073en_US
dc.subjectTuberculosisen_US
dc.subjectRifampicinen_US
dc.subjectExtended releaseen_US
dc.subjectHot melt extrusionen_US
dc.subjectDissolutionen_US
dc.titleDevelopment of extended release matrices of rifampicin using hot melt extrusion technique.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
japs2013v3n10p30.pdf
Size:
927.58 KB
Format:
Adobe Portable Document Format
Description:
Research article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal of Applied Pharmaceutical Science (JAPS)